Trial Profile
An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 23 Apr 2019 Results assessing safety and efficacy for the prevention of antibody-mediated rejection after transplantation in patients with donor-specific antibodies published in the American Journal of Transplantation
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.